Imugene Limited (IMU.XA)
Cboe AU - Cboe AU Real-time price. Currency in AUD
Add to watchlist
At close: 03:59PM AEST
| Previous close | 0.0550 |
| Open | 0.0550 |
| Bid | 0.0530 x N/A |
| Ask | 0.0550 x N/A |
| Day's range | 0.0540 - 0.0570 |
| 52-week range | 0.0390 - 0.1900 |
| Volume | |
| Avg. volume | 10,030,924 |
| Market cap | N/A |
| Beta (5Y monthly) | 3.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0050 |
| Earnings date | 30 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireThree Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)
10 patients have been treated to date with azer-cel in the Phase 1b diffuse large B-cell lymphoma (DLBCL) trial Cohort A: 6 patients were treated with azer-cel and lymphodepletion (chemotherapy)1Cohort B: 4 patients were treated with azer-cel, lymphodepletion (chemotherapy)1, and interleukin 2 (IL-2) 3 complete responses - The first 2 patients treated in Cohort B achieved a complete response (CR) and 1 patient treated in Cohort A achieved a CRDurability of CRs in Cohort B; >120 days and >90 days
Simply Wall St.Breakeven On The Horizon For Imugene Limited (ASX:IMU)
Imugene Limited ( ASX:IMU ) is possibly approaching a major achievement in its business, so we would like to shine some...
- Simply Wall St.
Is Imugene (ASX:IMU) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
© 2024 Yahoo. All rights reserved.